Scientists developed an experimental oral treatment for diabetes and obesity that activates skeletal muscle metabolism to lower blood sugar without causing appetite suppression linked to GLP-1 drugs. The pill targets a pathway distinct from injectable semaglutide-class medications.
GLP-1 agonists reduce weight partly by curbing hunger, an effect some patients find difficult to tolerate. A muscle-metabolism approach could offer glycemic control for patients seeking alternatives without nausea or reduced food intake.
Preclinical and early trial data suggested the compound increases glucose uptake through muscle tissue energetics. Researchers positioned the drug as complementary rather than directly competitive with established GLP-1 therapies.
Oral dosing improves convenience compared with weekly injections dominating current obesity pharmacotherapy. Further trials will establish efficacy, safety, and durability relative to existing standards of care.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/